BiotechTube

Saquinavir

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

IDV Associated Nephrotoxicity

Conditions

IDV Associated Nephrotoxicity

Trial Timeline

May 1, 2004 → May 1, 2008

NCT ID
NCT00477048

About Saquinavir

Saquinavir is a phase 2 stage product being developed by Roche for IDV Associated Nephrotoxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT00477048. Target conditions include IDV Associated Nephrotoxicity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT00002383Phase 1Completed
NCT00002382Phase 3Completed
NCT00002425ApprovedCompleted
NCT00002229ApprovedCompleted
NCT00477048Phase 2Completed

Competing Products

20 competing products in IDV Associated Nephrotoxicity

See all competitors
ProductCompanyStageHype Score
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
44
SatralizumabChugai PharmaceuticalPhase 3
77
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
23
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
PravastatinDaiichi SankyoPre-clinical
23
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
tacrolimusAstellas PharmaPre-clinical
23
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
77
roxadustat + darbepoetin alfaAstellas PharmaPhase 2
52
Tamsulosin OCASAstellas PharmaApproved
85
ISV-305Sun PharmaceuticalPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
donepezil hclEisaiPhase 3
77
Zonegran + sugar pillEisaiPhase 3
77
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
77
avatrombopag + PlaceboEisaiPhase 2
52

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85